CY1110123T1 - Φορεις eiav βελτιστοποιημενων κωδικονιων - Google Patents
Φορεις eiav βελτιστοποιημενων κωδικονιωνInfo
- Publication number
- CY1110123T1 CY1110123T1 CY20101100538T CY101100538T CY1110123T1 CY 1110123 T1 CY1110123 T1 CY 1110123T1 CY 20101100538 T CY20101100538 T CY 20101100538T CY 101100538 T CY101100538 T CY 101100538T CY 1110123 T1 CY1110123 T1 CY 1110123T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nucleotide sequence
- eiav
- options
- iii
- producer cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Semiconductor Lasers (AREA)
Abstract
Μέθοδος παραγωγής ρετροϊού ελλειμματικού αναδιπλασιασμού που περιλαμβάνει διαμόλυνση κυττάρου-παραγωγού με τα ακόλουθα: (i) ρετροϊικό γονιδίωμα, (ii) αλληλουχία νουκλεοτιδίων που κωδικοποιεί ρετροϊικές πρωτεΐνες gag και pol, και (iii) αλληλουχίες νουκλεοτιδίων που κωδικοποιούν άλλα απαραίτητα συστατικά ιικής συσκευασίας που δεν κωδικοποιούνται από την αλληλουχία νουκλεοτιδίων του (ii), που χαρακτηρίζεται από το ότι η αλληλουχία νουκλεοτιδίων που κωδικοποιεί τις ρετροιϊκές πρωτεΐνες gag και pol περιέχει κωδικόνια βελτιστοποιημένα για έκφραση στο κύτταρο-παραγωγό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0009760.0A GB0009760D0 (en) | 2000-04-19 | 2000-04-19 | Method |
EP01921651A EP1278878B1 (en) | 2000-04-19 | 2001-04-18 | Codon optimized eiav vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110123T1 true CY1110123T1 (el) | 2015-01-14 |
Family
ID=9890278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100538T CY1110123T1 (el) | 2000-04-19 | 2010-06-11 | Φορεις eiav βελτιστοποιημενων κωδικονιων |
Country Status (14)
Country | Link |
---|---|
US (3) | US20050042234A1 (el) |
EP (2) | EP1278878B1 (el) |
JP (1) | JP4981231B2 (el) |
CN (2) | CN1254543C (el) |
AT (1) | ATE462796T1 (el) |
AU (1) | AU4861901A (el) |
CA (1) | CA2404129A1 (el) |
CY (1) | CY1110123T1 (el) |
DE (1) | DE60141690D1 (el) |
DK (2) | DK2194137T3 (el) |
ES (2) | ES2618508T3 (el) |
GB (1) | GB0009760D0 (el) |
PT (1) | PT1278878E (el) |
WO (1) | WO2001079518A2 (el) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2344208A1 (en) | 2001-04-30 | 2002-10-30 | Oxford Biomedica (Uk) Limited | Method |
US9738907B2 (en) | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
JP4598398B2 (ja) * | 2002-02-01 | 2010-12-15 | オックスフォード バイオメディカ (ユーケー) リミテッド | ウイルスベクター |
AU2003225544A1 (en) * | 2002-02-04 | 2003-09-02 | Novartis Ag | Recombinant bovine immunodeficiency virus based gene transfer system |
WO2005118809A2 (en) | 2004-04-29 | 2005-12-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for enhancing cell adhesion properties |
TW200613554A (en) * | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
GB0526210D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Vectors |
JP5615271B2 (ja) | 2008-06-18 | 2014-10-29 | オックスフォード バイオメディカ(ユーケー)リミテッド | ウイルス精製法 |
DK2575894T3 (en) | 2010-05-28 | 2015-05-26 | Oxford Biomedica Ltd | FEED lentiviral vectors FOR BRAIN |
GB201118636D0 (en) | 2011-10-28 | 2011-12-07 | Oxford Biomedica Ltd | Nucleotide sequence |
CN106062201B (zh) | 2013-10-24 | 2020-11-06 | 圣拉法埃莱医院有限公司 | 方法 |
GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
RU2745705C2 (ru) | 2014-09-15 | 2021-03-30 | МОЛМЕД СпА | Химерные рецепторы антигенов |
GB201418965D0 (el) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
US20190017096A1 (en) | 2016-03-10 | 2019-01-17 | Nightstarx Limited | Prenylation assay |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
EP3318285A1 (en) | 2016-11-08 | 2018-05-09 | Oxford University Innovation Limited | Treatment of eye disease |
CN108130333A (zh) * | 2016-12-01 | 2018-06-08 | 上海泽润生物科技有限公司 | 重组脊髓灰质炎ⅰ型病毒样颗粒 |
US20200224195A1 (en) | 2016-12-01 | 2020-07-16 | Nestec S.A. | Methods of modulating fam46a |
EP3375876A1 (en) | 2017-03-13 | 2018-09-19 | Evonetix Ltd | Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures |
KR20230166145A (ko) | 2017-03-15 | 2023-12-06 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
JP2020515551A (ja) | 2017-03-31 | 2020-05-28 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Ank1を調節する方法 |
GB201706121D0 (en) * | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Stable cell lines for retroviral production |
EP3612624A1 (en) | 2017-04-21 | 2020-02-26 | Ospedale San Raffaele S.r.l. | Gene therapy |
TWI835730B (zh) | 2017-04-24 | 2024-03-21 | 義大利聖拉斐爾醫院 | Tcr及肽 |
WO2019068854A1 (en) | 2017-10-06 | 2019-04-11 | Ospedale San Raffaele S.R.L. | GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS |
US20200341015A1 (en) | 2017-10-17 | 2020-10-29 | Nightstarx Ltd. | Prenylation assay |
JP7477448B2 (ja) | 2017-11-21 | 2024-05-01 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Alkを調節する方法 |
GB201720948D0 (en) * | 2017-12-15 | 2018-01-31 | Autolus Ltd | Plasmid system |
EP3696272A1 (en) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviral vector |
WO2019134866A1 (en) | 2018-01-03 | 2019-07-11 | Molmed Spa | Chimeric antigen receptors containing optimal spacer region |
AU2019269593A1 (en) | 2018-05-15 | 2020-11-26 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
JP2021526361A (ja) | 2018-05-17 | 2021-10-07 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | Nkx6.3を調節する方法 |
KR20210016567A (ko) | 2018-05-30 | 2021-02-16 | 글리코스템 떼라퓨틱스 비.브이. | Car nk 세포 |
WO2020014209A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
GB201817821D0 (en) | 2018-10-31 | 2018-12-19 | Ospedale San Raffaele Srl | TCR and peptides |
AU2019378881A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for CNS delivery |
AU2019378883A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
AU2019380517A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
EP3898947A1 (en) | 2018-12-19 | 2021-10-27 | King's College London | Immunotherapeutic methods and compositions |
GB201900687D0 (en) | 2019-01-17 | 2019-03-06 | King S College London | Immunotherapeutic methods and compositions |
GB201902277D0 (en) | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
KR20220034719A (ko) | 2019-03-10 | 2022-03-18 | 시오 진 테라피스 인코포레이티드 | 파킨슨병을 치료하기 위한 유전자 요법 조성물 및 방법 |
GB201905301D0 (en) | 2019-04-15 | 2019-05-29 | Ospedale San Raffaele Srl | Gene therapy |
GB201907493D0 (en) | 2019-05-28 | 2019-07-10 | Ospedale San Raffaele | Agents and methods for treating viral infections |
GB201912515D0 (en) | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
AU2020341454A1 (en) | 2019-09-03 | 2022-03-10 | Sana Biotechnology, Inc. | CD24-associated particles and related methods and uses thereof |
WO2021094752A1 (en) | 2019-11-12 | 2021-05-20 | Oxford Biomedica (Uk) Limited | Production system |
CN115667533A (zh) | 2020-02-13 | 2023-01-31 | 牛津生物医学(英国)有限公司 | 慢病毒载体的生产 |
CN115427440A (zh) | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
KR20220154734A (ko) | 2020-03-13 | 2022-11-22 | 옥스포드 바이오메디카(유케이) 리미티드 | 렌티바이러스 벡터 |
EP4127144A1 (en) | 2020-03-31 | 2023-02-08 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
GB202007169D0 (en) | 2020-05-14 | 2020-07-01 | Ospedale San Raffaele Srl | Epidermal growth factor receptor |
GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
WO2021236852A1 (en) | 2020-05-20 | 2021-11-25 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
EP4204447A1 (en) | 2020-08-28 | 2023-07-05 | Sana Biotechnology, Inc. | Modified anti-viral binding agents |
GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
GB202018657D0 (en) | 2020-11-26 | 2021-01-13 | Ospedale San Raffaele Srl | Agents and methods for increasing liver immune response |
CN112430582B (zh) * | 2020-12-04 | 2022-05-03 | 北京艺妙神州医药科技有限公司 | 一种慢病毒稳定包装细胞系及其制备方法 |
WO2022136874A1 (en) | 2020-12-23 | 2022-06-30 | Quell Therapeutics Limited | Inducible signalling protein |
TW202242121A (zh) | 2021-01-11 | 2022-11-01 | 美商薩那生物科技公司 | 靶向cd8之病毒載體之用途 |
AU2022213505A1 (en) | 2021-02-01 | 2023-09-07 | Epsilen Bio S.R.L. | Gene silencing |
CA3207426A1 (en) | 2021-02-15 | 2022-08-18 | Vania Broccoli | Epigenetic silencing for treatment of cancer |
GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
GB202102832D0 (en) * | 2021-02-26 | 2021-04-14 | Ip2Ipo Innovations Ltd | Retroviral vectors |
CA3218631A1 (en) | 2021-05-12 | 2022-11-17 | Alberto Auricchio | Vector system |
EP4347620A1 (en) | 2021-05-28 | 2024-04-10 | Sana Biotechnology, Inc. | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
EP4381081A1 (en) | 2021-08-04 | 2024-06-12 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
WO2023077107A1 (en) | 2021-10-29 | 2023-05-04 | Sana Biotechnology, Inc. | Methods and reagents for amplifying viral vector nucleic acid products |
GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
AU2022422880A1 (en) | 2021-12-22 | 2024-05-30 | Quell Therapeutics Limited | Constitutive cytokine receptors |
EP4209511A1 (en) | 2022-01-05 | 2023-07-12 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies amd chimeric antigen receptors |
WO2023131657A1 (en) | 2022-01-05 | 2023-07-13 | Gyala Therapeutics Sociedad Limitada | Anti-cd84 antibodies and chimeric antigen receptors |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
EP4269426A1 (en) | 2022-04-29 | 2023-11-01 | Ospedale San Raffaele S.r.l. | Gene therapy |
WO2024008950A1 (en) | 2022-07-08 | 2024-01-11 | Ospedale San Raffaele S.R.L. | Transgene cassettes |
EP4303226A1 (en) | 2022-07-08 | 2024-01-10 | Ospedale San Raffaele S.r.l. | Transgene cassettes and epigenetic silencers for the treatment of disorders |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024033544A1 (en) | 2022-08-12 | 2024-02-15 | Ospedale San Raffaele S.R.L. | Deglycosylation of native glycoproteins expressed on a tumor cell surface |
GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024100145A1 (en) | 2022-11-08 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Polynucleotide and vector |
WO2024100294A1 (en) | 2022-11-11 | 2024-05-16 | Ospedale San Raffaele S.R.L. | Cdh17 car |
GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0301293B2 (de) | 1987-07-29 | 1995-08-30 | BASF Lacke + Farben AG | Kathodisch abscheidbare Kunstharze enthaltende wässrige Elektrotauchlackbäder und Verfahren zur Beschichtung elektrisch leitfähiger Substrate |
AU6075190A (en) | 1989-06-30 | 1991-01-17 | Regents Of The University Of California, The | Retrovirus detection |
EP0854193A1 (en) | 1990-09-21 | 1998-07-22 | Chiron Corporation | Human retroviral packaging cell line |
US6013517A (en) * | 1994-05-09 | 2000-01-11 | Chiron Corporation | Crossless retroviral vectors |
US5786464C1 (en) * | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
WO1996009400A1 (en) | 1994-09-19 | 1996-03-28 | Systemix, Inc. | Methods for genetically modifying hematopoietic stem cells |
US5723315A (en) | 1996-08-23 | 1998-03-03 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP0859856A2 (en) | 1995-11-08 | 1998-08-26 | Whitehead Institute For Biomedical Research | Stable packaging cell line producing pseudotyped retroviruses |
JP2000517297A (ja) | 1996-08-07 | 2000-12-26 | ダーウィン・ディスカバリー・リミテッド | Mmpとtnfの抑制活性を有するヒドロキサム酸誘導体およびカルボン酸誘導体 |
US5739018A (en) | 1996-08-07 | 1998-04-14 | The Regents Of The University Of California | Packaging cell lines for pseudotyped retroviral vectors |
US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
US6696291B2 (en) * | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
AU741747B2 (en) * | 1997-05-13 | 2001-12-06 | University Of North Carolina At Chapel Hill, The | Lentivirus-based gene transfer vectors |
NZ503318A (en) | 1997-09-23 | 2001-11-30 | Oxford Biomedica Ltd | Modified haemopoietic stem cell comprised of a spliced upstream with a nucleotide sequence of interest to be used as in gene therapy |
GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
CN1322137C (zh) * | 1997-12-22 | 2007-06-20 | 牛津生物医学(英国)有限公司 | 基于马传染性贫血病毒(eiav)的逆转录病毒载体 |
GB9803351D0 (en) * | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
AU6139699A (en) * | 1998-09-11 | 2000-04-03 | Children's Medical Center Corporation | Packaging cell lines for hiv-derived retroviral vector particles |
US6958226B1 (en) * | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
CA2360347C (en) * | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
GB9906177D0 (en) * | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
HUP0201019A2 (en) * | 1999-04-26 | 2002-08-28 | Leuven K U Res & Dev | Synthetic gene for expressing active retroviral protein in eukaryotes |
GB9923558D0 (en) * | 1999-10-05 | 1999-12-08 | Oxford Biomedica Ltd | Producer cell |
-
2000
- 2000-04-19 GB GBGB0009760.0A patent/GB0009760D0/en not_active Ceased
-
2001
- 2001-04-18 CA CA002404129A patent/CA2404129A1/en not_active Abandoned
- 2001-04-18 EP EP01921651A patent/EP1278878B1/en not_active Expired - Lifetime
- 2001-04-18 DK DK10158183.3T patent/DK2194137T3/en active
- 2001-04-18 EP EP10158183.3A patent/EP2194137B1/en not_active Expired - Lifetime
- 2001-04-18 CN CNB018084044A patent/CN1254543C/zh not_active Expired - Lifetime
- 2001-04-18 DK DK01921651.4T patent/DK1278878T3/da active
- 2001-04-18 ES ES10158183.3T patent/ES2618508T3/es not_active Expired - Lifetime
- 2001-04-18 DE DE60141690T patent/DE60141690D1/de not_active Expired - Lifetime
- 2001-04-18 US US10/258,089 patent/US20050042234A1/en not_active Abandoned
- 2001-04-18 WO PCT/GB2001/001784 patent/WO2001079518A2/en active Application Filing
- 2001-04-18 ES ES01921651T patent/ES2343564T3/es not_active Expired - Lifetime
- 2001-04-18 JP JP2001577501A patent/JP4981231B2/ja not_active Expired - Lifetime
- 2001-04-18 AT AT01921651T patent/ATE462796T1/de active
- 2001-04-18 AU AU4861901A patent/AU4861901A/xx active Pending
- 2001-04-18 CN CN200610067908XA patent/CN101024845B/zh not_active Expired - Lifetime
- 2001-04-18 PT PT01921651T patent/PT1278878E/pt unknown
-
2008
- 2008-03-20 US US12/077,802 patent/US20080269473A1/en not_active Abandoned
-
2009
- 2009-10-02 US US12/587,236 patent/US20100273996A1/en not_active Abandoned
-
2010
- 2010-06-11 CY CY20101100538T patent/CY1110123T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001079518A3 (en) | 2002-05-16 |
GB0009760D0 (en) | 2000-06-07 |
EP1278878B1 (en) | 2010-03-31 |
DK2194137T3 (en) | 2017-03-20 |
ES2618508T3 (es) | 2017-06-21 |
CN1426477A (zh) | 2003-06-25 |
AU2001248619B2 (en) | 2006-06-15 |
ATE462796T1 (de) | 2010-04-15 |
ES2343564T3 (es) | 2010-08-04 |
DE60141690D1 (de) | 2010-05-12 |
JP4981231B2 (ja) | 2012-07-18 |
JP2004508808A (ja) | 2004-03-25 |
PT1278878E (pt) | 2010-05-31 |
US20050042234A1 (en) | 2005-02-24 |
EP1278878A2 (en) | 2003-01-29 |
AU4861901A (en) | 2001-10-30 |
US20080269473A1 (en) | 2008-10-30 |
EP2194137B1 (en) | 2016-12-21 |
US20100273996A1 (en) | 2010-10-28 |
CN101024845A (zh) | 2007-08-29 |
CN1254543C (zh) | 2006-05-03 |
CA2404129A1 (en) | 2001-10-25 |
EP2194137A2 (en) | 2010-06-09 |
WO2001079518A2 (en) | 2001-10-25 |
CN101024845B (zh) | 2013-01-16 |
DK1278878T3 (da) | 2010-06-28 |
EP2194137A3 (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110123T1 (el) | Φορεις eiav βελτιστοποιημενων κωδικονιων | |
ES8800343A1 (es) | Un metodo para producir una proteina que contiene actividad biologica para coagulacion de sangre, mediada por factor viia | |
ATE140571T1 (de) | Digitales codierverfahren | |
IL146144A0 (en) | Method and means for producing high titer, safe, recombinant lentivirus vectors | |
JP2004508808A5 (el) | ||
GB2369121A (en) | Producer cell for the production of retroviral vectors | |
ATE308614T1 (de) | Durch pflanzen hergestelltes rekombinantes kollagen, verfahren zu ihrer herstellung und verwendung | |
AP8600035A0 (en) | Hepatitis B surface antigen formed by recombinant DNA Techniques, vaccines, diagnostics, cell lines and methods of forming same. | |
DK21385A (da) | Fremgangsmaade ved kodning af n-bit-informationsord til m-bit-kodeord og ved dekodning af m-bit-kodeord til n-bit-informationsord, samt apparat til udoevelse af naevnte fremgangsmaader | |
AU7659298A (en) | Recombinant lactoferrin, methods of production from plants and uses | |
DK0874057T3 (da) | Vektor og pattedyrcellelinie med forbedret produktionsevne | |
ES2125530T3 (es) | Secuencia de acidos nucleicos que codifica una enzima semejante a tripsina y procedimiento para producir la enzima. | |
NO20003146L (no) | Ketonperoksyd-derivater, deres fremstilling og anvendelse | |
DK0516647T3 (da) | Polypeptider, som er involveret i biosyntesen af cobalaminer og/eller cobamider, DNA-sekvenser, som koder for disse polypep | |
MX9206630A (es) | Microorganismos con plasmidos estables. | |
DE69110897D1 (de) | Hemmung der viralen replikation. | |
EP0422217A4 (en) | Human recombinant placental ribonuclease inhibitor and method of production | |
DK260188D0 (da) | Enzymproduktion | |
NL960017I1 (nl) | Expressie van Factor VIII-activiteit in zoogdiercellen. | |
DK130290D0 (da) | Lymfokiner, dna-sekvenser, som koder for disse lymfokiner og farmaceutiske midler indeholdende disse lymfokiner | |
WO2004027066A3 (fr) | Protéine recombinante chimérique et diagnostic in vitro du hiv | |
ATE489331T1 (de) | Auf wasserstoffperoxid basierendes verfahren zur erzeugung von chlordioxid | |
ES2069614T3 (es) | Gen del citocromo c de una bacteria que utiliza el hidrogeno. | |
ATE110112T1 (de) | Verfahren und systeme zur herstellung von hiv- antigenen. | |
DE50009777D1 (de) | Verfahren zur Herstellung von Halogenen durch Gasphasenelektrolyse |